Table 4.
Table comparing the unfavourable sites of involvement among patients who underwent CC and MTD for malignant peritoneal mesothelioma
| Unfavourable sites | Site (n) | CC (n = 22) | MTD (n = 12) | p value |
|---|---|---|---|---|
| Epigastric region | Lesser omentum – 10 | 4 (18.1%) | 6 (50%) | 0.062 |
| Disease around left lobe of liver – 3 | 2 (9%) | 1 (8.2%) | 0.721 | |
| Perigastric disease – 5 | 1 (4.5%) | 4 (33.3%) | 0.042 | |
| Porta hepatis – 8 | 4 (18.1%) | 4 (33.3%) | 0.279 | |
| CBD obstruction – 0 | 0 (0) | 0 (0) | ||
| Paraduodenal disease – 0 | 0 (0) | 0 (0) | ||
| Liver involvement – 1 | 0 (0) | 1 (8.2%) | ||
| Splenic involvement – 2 | 0 (0) | 2 (16.6%) | ||
| Mesentery and small bowel | Mesentery – 24 | 14 (63.6%) | 10 (83.3%) | 0.211 |
| Root of mesentery – 0 | 0 (0) | 0 (0) | ||
| Small bowel – 16 | 7 (33.3%) | 9 (75%) | 0.019 | |
| Retroperitoneum | Hydronephrosis – 1 | 0 (0) | 1 (8.2%) | |
| Bladder trigone – 1 | 0 (0) | 1 (8.2%) | ||
| Pelvic side wall – 0 | 0 (0) | 0 (0) | ||
| Lymphnodes | Retroperitoneum and abdomen – 1 | 0 (0) | 1 (8.2%) | 0.279 |
| Epiphrenic – 8 | 4 (18.1%) | 4 (33.3%) | ||
| Concurrent intrathoracic disease | Pleural effusion and pleural nodules – 2 | 0 (0) | 2 (16.6%) | |
| Abdominal wall disease | Abdominal wall nodules – 4 | 2 (9%) | 2 (16.6%) | 0.444 |